← Eichor
Study identifier: NCT07083531 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Bone Loss, Physical Function and Frailty in Older Women With Sickle Cell Trait Sickle Cell Trait

Condition: Sickle Cell Disease · Sickle Cell Trait  ·  Sponsor: UConn Health

PhaseN/A
Planned participants50
Who can joinFemale, 50 Years to no upper limit
Healthy volunteersYes

About this study

This is a cross-sectional, clinical research study comparing postmenopausal women of African Descent (AD) with different hemoglobin genotypes: normal and sickle cell trait (SCT). This research study has two purposes. The first purpose is to determine whether having SCT is a risk factor for the development of bone thinning in older women. The second purpose is to investigate whether women with SCT have reduced muscle function and increased frailty compared to women without SCT. The investigators estimate enrolling 50 female volunteers who are at least 50 years old and have not had a menstrual period for at least 12 consecutive months. Volunteers need not know whether they have SCT as this will be evaluated as part of the study.

This description comes directly from the study's public registry record.

Talk to the study team

Zoe Green, BS  ·  860.679.4656  ·  zgreen@uchc.edu

Always discuss trial participation with your own doctor first.

Locations (1)

UConn HealthFarmington, Connecticut, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07083531